BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32616627)

  • 1. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
    Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
    Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-operative pancreatic fistula following splenectomy with or without distal pancreatectomy at cytoreductive surgery in advanced ovarian cancer.
    Bizzarri N; Korompelis P; Ghirardi V; O'Donnell RL; Rundle S; Naik R
    Int J Gynecol Cancer; 2020 Jul; 30(7):1043-1051. PubMed ID: 32546641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Nica A; Covens A; Parra-Herran C; May T
    Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery.
    Jones NL; Chen L; Chatterjee S; Tergas AI; Burke WM; Hou JY; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Int J Gynecol Cancer; 2018 Jan; 28(1):19-25. PubMed ID: 28953134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
    Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
    Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
    Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.
    Cham S; Chen L; St Clair CM; Hou JY; Tergas AI; Melamed A; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Am J Obstet Gynecol; 2019 Jun; 220(6):571.e1-571.e8. PubMed ID: 30771346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
    Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
    Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
    Horner W; Peng K; Pleasant V; Brackmann M; Ebott J; Gutfreund R; McLean K; Reynolds RK; Uppal S
    Gynecol Oncol; 2019 Aug; 154(2):283-289. PubMed ID: 31196575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
    Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
    Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
    Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
    Rush SK; Lees BF; Huang DS; Peterson MF; Al-Niaimi A
    Gynecol Oncol; 2022 Nov; 167(2):283-288. PubMed ID: 36114028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity of multiple bowel resection compared to single bowel resection after debulking surgery for ovarian cancer.
    Tozzi R; Casarin J; Baysal A; Pinelli C; Matak L; Ghanbarzadeh N; Alazzam M; Garruto-Campanile R; Majd HS; Kilic Y; Morotti M
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():215-219. PubMed ID: 31326636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.